Copaxone® (glatiramer acetate)
- Parent company: Teva Neuroscience, Inc.
- Given through daily subcutaneous injections
Approved for RRMS.
- Has anti-inflammatory properties and may have a neuroprotective effect.
- Study with primary-progressive multiple sclerosis (PPMS) was stopped due to lack of effectiveness; in a subsequent analysis, may be effective for men, but more studies needed.
- A pilot study with double-dose Copaxone looks encouraging, with a reduction in relapses and lesions as seen on magnetic resonance imaging (MRI).
- Study being conducted with a double-dose of Copaxone (FORTE study).
- An ongoing trial combines Copaxone with Avonex (COMBI Rx trial).
- Another study looks at Copaxone combined with minocycline (an inexpensive, oral antibiotic); the combination reflected consistent pattern of benefit in reduction of new and active lesions; also reported to be safe and well tolerated.
- Being tested in the treatment of CIS (PreCISe study).